Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
WTVI .002 Wi-Fi TV(TM) to Be Featured at Global Investment Conference in Dubai With Founder's Presentation to Be Webcast Live to World Audience
Wi-Fi TV's Social Internet TV and Web Communication Platform to Gain Attention of Fund Managers, Bankers and Media From Around the World
Jun 21, 2007 9:15:00 AM
DUBAI, UAE -- (MARKETWIRE) -- 06/21/07 -- Wi-Fi TV Inc. (PINKSHEETS: WTVI) announced today that its Founder and Chairman has accepted an invitation to make a live presentation that will be webcast before a global audience, archived online for a year, and be seen live by fund managers, bankers, investors and media gathered in Dubai for the Wall Street Reporter's Global Investment Conference on December 3rd through 5th.
"We believe that Dubai provides the right investment environment, coupled with the amazing reach of a live global webcast from this distinctive venue, to bring Wi-Fi TV to the next level of exposure. Wi-Fi TV will have already launched the next generation of our website prior to the forum, which provides a unique and focused array of truly interactive TV, in an environment where people can share their interests through live chat, free calls and free video party rooms. We look forward to being part of the exciting Wall Street Reporter event," said Wi-Fi TV Inc. Founder and Chairman Alex Kanakaris.
"Our goal is to bring Wi-Fi TV to the largest possible Internet audience, and at the same time let the leaders of the global investment community know how we are positioned to be a significant force in the creation and delivery of Social Internet TV," Mr. Kanakaris added.
Following the Wi-Fi TV presentation which will be part of a live global webcast, the Wi-Fi TV Founder will be interviewed by Wall Street Reporter Television and this interview will be syndicated as a podcast through Apple iTunes, YouTube and other global video feeds, and will be featured on the home page of the Wall Street Reporter's website.
Wi-Fi TV(TM) Is A Pioneer Of TV On The Internet
Wi-Fi TV Inc. has long touted the coming convergence of TV and the Internet, and provided the first online movie in December 1995. The Wi-Fi TV website is the only place on the Internet where you can watch hundreds of TV stations and chat with others watching the same program in a live chat box directly under the viewing screen, and get breaking news for each country and category listed, and download a dialer and make free phone calls and host live video parties all on one website.
About Wi-Fi TV Inc.
Wi-Fi TV Inc. provides Social Internet TV(TM), a new generation TV delivery platform that has a geographic sphere out-distancing any traditional cable or over-the-air TV broadcaster. Wi-Fi TV memberships are free at www.Wi-FiTV.com and include such perks as free online phone calls and free chat and free online parties.
The Company was launched in 1995 and has been publicly traded since November 1997, and has been a pioneer in the delivery of video and books over the Internet.
Press Relations
Wi-Fi TV Inc. has opened a content and technology demo room for the press in Newport Beach, California. For further information contact Colby Marceau, (949) 716-9397, info@wi-fitv.com.
Forward-Looking Statements
Any statements made in this press release which are not historical facts contain certain forward-looking statements; as such term is defined in the Private Security Litigation Reform Act of 1995, concerning potential developments affecting the business, prospects, financial condition and other aspects of the company to which this release pertains. The actual results of the specific items described in this release, and the company's operations generally, may differ materially from what is projected in such forward-looking statements. Although such statements are based upon the best judgments of management of the company as of the date of this release, significant deviations in magnitude, timing and other factors may result from business risks and uncertainties including, without limitation, the company's dependence on third parties, general market and economic conditions, technical factors, the availability of outside capital, receipt of revenues and other factors, many of which are beyond the control of the company. The company disclaims any obligation to update information contained in any forward-looking statement. Wi-Fi TV and Social Internet TV are trademarks of Wi-Fi TV Inc. and all rights pertaining to these names are reserved. This press release shall not be deemed a general solicitation.
Contact:
Colby Marceau
(949) 716-9397
Email Contact
NSHV L2 BID UT
AERO 7.00 AeroGrow Launches Full-Line Product Catalog of Kitchen Gardening Systems, Seed Kits and Accessories
National Direct Marketing Sales Initiative Launched With More Than 50,000 Catalogs Mailed to Targeted Lists and the AeroGrow House File
Jun 21, 2007 9:15:00 AM
BOULDER, CO -- (MARKETWIRE) -- 06/21/07 -- AeroGrow International, Inc. (NASDAQ: AERO) ("AeroGrow" or the "Company"), makers of the AeroGarden� kitchen garden appliance, announced today the release of its first full-line print catalog (click here to view the catalog). The 16-page, full color catalog features 31 AeroGarden products and accessories, including 19 new products. The new products include 9 Seed Kits, 9 accessories, and the new AeroGarden Pro 100, which features stylish stainless steel trim and AeroGrow's newest and best Adaptive Growth Intelligence(TM) technology.
The catalog is generating revenue in four primary ways:
1. Included in AeroGarden boxes sold in retail stores to introduce the full product line to existing users and encourage repeat sales;
2. Included with all future direct product shipments from AeroGrow;
3. Mailed to AeroGrow's growing house list for repeat sales of Seed Kits, Grow Bulbs, accessories and additional AeroGardens; and
4. Mass mailed to prospective customers from targeted lists modeled after AeroGrow's existing customer demographics or related interests such as gardening, cooking and healthy eating.
"Over the last 15 months we've collected detailed demographic information about who our customers are and why they are buying our products," stated AeroGrow founder and CEO Michael Bissonnette. "Our direct mail catalog initiative will allow us the opportunity to expand our revenue base by directly targeting the millions of consumers who share similar interests and lifestyles and introducing them to our product line. In addition, we're creating detailed models for mailing our house file at regular intervals based on purchase dates and usage in order to increase our repeat sales of Seed Kits, Grow Bulbs and additional gardens."
About AeroGrow International, Inc.
Founded in 2002 in Boulder, Colorado, AeroGrow International, Inc. is dedicated to the research, development and marketing of the AeroGarden�, the world's first kitchen garden appliance. The AeroGarden features NASA-proven, dirt-free aeroponic technology, allowing anyone to grow farmer's market fresh herbs, salad greens, tomatoes, chili peppers, strawberries and more, indoors, year-round, so simply and easily that no green thumb is required. See www.aerogrow.com.
FORWARD-LOOKING STATEMENTS
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements by the Company, statements regarding growth of the AeroGarden product line, optimism related to the business, expanding sales and other statements in this press release are forward-looking statements within the meaning of the Securities Litigation Reform Act of 1995. Such statements are based on current expectations, estimates and projections about the Company's business. Words such as expects, anticipates, intends, plans, believes, sees, estimates and variations of such words and similar expressions are intended to identify such forward-looking statements. These statements are not guarantees of future performance and involve certain risks and uncertainties that are difficult to predict. Actual results could vary materially from the description contained herein due to many factors including continued market acceptance of the Company's products or the need to raise additional capital. In addition, actual results could vary materially based on changes or slower growth in the kitchen garden appliance market; the potential inability to realize expected benefits and synergies; domestic and international business and economic conditions; changes in customer demand or ordering patterns; changes in the competitive environment including pricing pressures or technological changes; technological advances; shortages of manufacturing capacity; future production variables impacting excess inventory and other risk factors listed from time to time in the Company's Securities and Exchange Commission (SEC) filings under "risk factors" and elsewhere. The forward-looking statements contained in this press release speak only as of the date on which they are made, and the Company does not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of this press release.
CONTACTS:
Corporate
John Thompson
AeroGrow International, Inc.
(303) 444-7755
john@aerogrow.com
Investor
Justin Davis
After Market Support, LLC
Toll Free: (800) 979-AGWI (2494)
justin.davis@aftermarketsupport.com
CEGE 3.77 Ceregene and Genzyme Announce Partnership for the Development and Commercialization of Cere-120 for Parkinson's Disease
Jun 21, 2007 9:07:00 AM
SAN DIEGO, Ca. and CAMBRIDGE, Mass., June 21 /PRNewswire-FirstCall/ -- Ceregene, Inc. and Genzyme Corporation (Nasdaq: GENZ) today announced that they have entered into a partnership for the development and commercialization of CERE-120, Ceregene's proprietary lead program for the treatment of Parkinson's disease.
Under the terms of the agreement, Genzyme will pay Ceregene a $25 million up-front payment in exchange for certain partnership-related expenses. Ceregene will also be entitled to development-related milestone payments of up to $125 million and 50 percent reimbursement of the worldwide Phase 3 development costs. Genzyme will gain marketing rights in all markets outside of the US and Canada, and Genzyme will pay Ceregene tiered royalties based on sales in markets where it has rights. Ceregene will retain exclusive rights to CERE-120 in the US and Canada.
"We are pleased to be partnering CERE-120 with Genzyme-a company with a strong international presence and marketing expertise that will enable us to maximize the worldwide commercialization of CERE-120," stated Jeffrey M. Ostrove, Ph.D., president and chief executive officer of Ceregene. "CERE-120, which is currently undergoing a controlled Phase 2 trial in the United States that is being partially funded by the Michael J. Fox Foundation, has demonstrated strong clinical and preclinical data to date and may have the ability to both improve Parkinson's disease symptoms and slow the disease progression. The resources provided by our new partnership with Genzyme, together with the greater than $27 million initial closing of our Series C financing, which was led by Investor Growth Capital and closed in the first quarter, provides the funding we currently need to advance CERE-120 toward commercialization."
"We are very enthusiastic about the potential that CERE-120 may have to improve the lives of people with Parkinson's disease, which currently affects at least one million Americans," said David Meeker, president, Lysosomal Storage Disorders unit, Genzyme Corporation. "We look forward to helping further the development of this exciting approach, building on our long-term commitment to gene therapy and neurodegenerative diseases. This program - which is focused on preserving neuronal function - will complement our existing Parkinson's clinical trial that is currently underway."
"We look forward to working with Genzyme to accelerate the development of CERE-120 in Europe and other areas outside North America," stated Raymond T. Bartus, Ph.D., Ceregene's senior vice president of clinical and preclinical R&D and chief operating officer, as well as chairman of the partnership's joint steering committee. "Strong synergies and complementary skills and experience exist between Ceregene and Genzyme. Their deep infrastructure in developing and commercializing innovative therapeutic products and their experience working with international regulatory agencies will be invaluable as we expand the development of CERE-120."
In a complementary program, Genzyme is conducting a separate Phase 1-2 clinical trial of a gene therapy for Parkinson's disease designed to restore the therapeutic effectiveness of levo-Dopa by enhancing the brain's ability to convert it into dopamine. In addition, Genzyme has an extensive gene therapy portfolio that includes two additional ongoing clinical trials.
About CERE-120
CERE-120 is composed of an adeno-associated virus (AAV) vector carrying the gene for neurturin (NTN), a naturally occurring protein known to repair damaged and dying dopamine-secreting neurons, keeping them alive and functioning normally. NTN is a member of the same protein family as glial cell-derived neurotrophic factor (GDNF). The two molecules have similar pharmacological properties, and both have been shown to benefit the midbrain dopamine neurons that degenerate in Parkinson's disease and are responsible for the major motor impairments. CERE-120 is delivered by stereotactic injection to the affected area of the brain, providing stable, long-lasting expression of NTN in a highly targeted fashion.
About CERE-120 Clinical Trials
Ceregene is currently conducting a Phase 2 clinical trial, which is in the process of enrolling 51 patients with advanced Parkinson's disease at nine medical centers in the United States. In a Phase 1 trial, CERE-120 demonstrated a 36 percent (p<0.001) reduction in Parkinson's symptoms at 12 months after administration, as measured by the Unified Parkinson's Disease Rating Scale (UPDRS) motor "off" score ("motor off" meaning patients were off Parkinson's medication at evaluation time). CERE-120 was also shown to be well tolerated in the study. The 12-month results were presented at the American Association of Neurological Surgeons (AANS) annual meeting in April 2007.
About Parkinson's Disease
Parkinson's disease is a progressive movement disorder that affects at least one million people in the United States. It is caused by a reduction in dopamine containing nerve cells of the midbrain. Dopamine is a neurotransmitter involved in controlling movement and coordination, so Parkinson's patients experiencing a reduction of dopamine-producing nerve cells exhibit the progressive inability to initiate and control physical movements. There is currently no cure for Parkinson's disease.
About Ceregene
Ceregene, Inc. is a San Diego-based biotechnology company focused on the development of gene therapies for neurodegenerative disorders. Ceregene is in the clinic with CERE-110, an AAV2 based vector expressing nerve growth factor that is being tested as a treatment for Alzheimer's disease, and with CERE-120 for Parkinson's disease. CERE-130 is in late preclinical development for amyotrophic lateral sclerosis (ALS). Ceregene was launched in January 2001 and is a former subsidiary of Cell Genesys, Inc. (Nasdaq: CEGE), which is headquartered in South San Francisco, CA. Ceregene's investors include Alta Partners, MPM Capital, Investor Growth Capital and Cell Genesys, as well as Hamilton BioVentures and California Technology Partners.
About Genzyme
One of the world's leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Since 1981, the company has grown from a small start-up to a diversified enterprise with more than 9,000 employees in locations spanning the globe and 2006 revenues of $3.2 billion. Genzyme has been selected by FORTUNE as one of the "100 Best Companies to Work for" in the United States.
With many established products and services helping patients in nearly 90 countries, Genzyme is a leader in the effort to develop and apply the most advanced technologies in the life sciences. The company's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant, and diagnostic testing. Genzyme's commitment to innovation continues today with a substantial development program focused on these fields, as well as immune disease, infectious disease, and other areas of unmet medical need.
Contacts: Jeffrey M. Ostrove, Ph.D.
President and CEO
Ceregene, Inc.
(858) 458-8808
Erin Emlock
Media
Genzyme Corporation
(617) 768-6923
Carol Miceli
Investors
Genzyme Corporation
(617) 768-6602
SOURCE Genzyme Corporation; Ceregene, Inc.
----------------------------------------------
Jeffrey M. Ostrove
Ph.D.
President and CEO of Ceregene
Inc.
+1-858-458-8808; or Media
Erin Emlock of Genzyme Corporation
+1-617-768-6923; or Investors
Carol Miceli of Genzyme Corporation
+1-617-768-6602
CEGE 3.77 Ceregene and Genzyme Announce Partnership for the Development and Commercialization of Cere-120 for Parkinson's Disease
Jun 21, 2007 9:07:00 AM
SAN DIEGO, Ca. and CAMBRIDGE, Mass., June 21 /PRNewswire-FirstCall/ -- Ceregene, Inc. and Genzyme Corporation (Nasdaq: GENZ) today announced that they have entered into a partnership for the development and commercialization of CERE-120, Ceregene's proprietary lead program for the treatment of Parkinson's disease.
Under the terms of the agreement, Genzyme will pay Ceregene a $25 million up-front payment in exchange for certain partnership-related expenses. Ceregene will also be entitled to development-related milestone payments of up to $125 million and 50 percent reimbursement of the worldwide Phase 3 development costs. Genzyme will gain marketing rights in all markets outside of the US and Canada, and Genzyme will pay Ceregene tiered royalties based on sales in markets where it has rights. Ceregene will retain exclusive rights to CERE-120 in the US and Canada.
"We are pleased to be partnering CERE-120 with Genzyme-a company with a strong international presence and marketing expertise that will enable us to maximize the worldwide commercialization of CERE-120," stated Jeffrey M. Ostrove, Ph.D., president and chief executive officer of Ceregene. "CERE-120, which is currently undergoing a controlled Phase 2 trial in the United States that is being partially funded by the Michael J. Fox Foundation, has demonstrated strong clinical and preclinical data to date and may have the ability to both improve Parkinson's disease symptoms and slow the disease progression. The resources provided by our new partnership with Genzyme, together with the greater than $27 million initial closing of our Series C financing, which was led by Investor Growth Capital and closed in the first quarter, provides the funding we currently need to advance CERE-120 toward commercialization."
"We are very enthusiastic about the potential that CERE-120 may have to improve the lives of people with Parkinson's disease, which currently affects at least one million Americans," said David Meeker, president, Lysosomal Storage Disorders unit, Genzyme Corporation. "We look forward to helping further the development of this exciting approach, building on our long-term commitment to gene therapy and neurodegenerative diseases. This program - which is focused on preserving neuronal function - will complement our existing Parkinson's clinical trial that is currently underway."
"We look forward to working with Genzyme to accelerate the development of CERE-120 in Europe and other areas outside North America," stated Raymond T. Bartus, Ph.D., Ceregene's senior vice president of clinical and preclinical R&D and chief operating officer, as well as chairman of the partnership's joint steering committee. "Strong synergies and complementary skills and experience exist between Ceregene and Genzyme. Their deep infrastructure in developing and commercializing innovative therapeutic products and their experience working with international regulatory agencies will be invaluable as we expand the development of CERE-120."
In a complementary program, Genzyme is conducting a separate Phase 1-2 clinical trial of a gene therapy for Parkinson's disease designed to restore the therapeutic effectiveness of levo-Dopa by enhancing the brain's ability to convert it into dopamine. In addition, Genzyme has an extensive gene therapy portfolio that includes two additional ongoing clinical trials.
About CERE-120
CERE-120 is composed of an adeno-associated virus (AAV) vector carrying the gene for neurturin (NTN), a naturally occurring protein known to repair damaged and dying dopamine-secreting neurons, keeping them alive and functioning normally. NTN is a member of the same protein family as glial cell-derived neurotrophic factor (GDNF). The two molecules have similar pharmacological properties, and both have been shown to benefit the midbrain dopamine neurons that degenerate in Parkinson's disease and are responsible for the major motor impairments. CERE-120 is delivered by stereotactic injection to the affected area of the brain, providing stable, long-lasting expression of NTN in a highly targeted fashion.
About CERE-120 Clinical Trials
Ceregene is currently conducting a Phase 2 clinical trial, which is in the process of enrolling 51 patients with advanced Parkinson's disease at nine medical centers in the United States. In a Phase 1 trial, CERE-120 demonstrated a 36 percent (p<0.001) reduction in Parkinson's symptoms at 12 months after administration, as measured by the Unified Parkinson's Disease Rating Scale (UPDRS) motor "off" score ("motor off" meaning patients were off Parkinson's medication at evaluation time). CERE-120 was also shown to be well tolerated in the study. The 12-month results were presented at the American Association of Neurological Surgeons (AANS) annual meeting in April 2007.
About Parkinson's Disease
Parkinson's disease is a progressive movement disorder that affects at least one million people in the United States. It is caused by a reduction in dopamine containing nerve cells of the midbrain. Dopamine is a neurotransmitter involved in controlling movement and coordination, so Parkinson's patients experiencing a reduction of dopamine-producing nerve cells exhibit the progressive inability to initiate and control physical movements. There is currently no cure for Parkinson's disease.
About Ceregene
Ceregene, Inc. is a San Diego-based biotechnology company focused on the development of gene therapies for neurodegenerative disorders. Ceregene is in the clinic with CERE-110, an AAV2 based vector expressing nerve growth factor that is being tested as a treatment for Alzheimer's disease, and with CERE-120 for Parkinson's disease. CERE-130 is in late preclinical development for amyotrophic lateral sclerosis (ALS). Ceregene was launched in January 2001 and is a former subsidiary of Cell Genesys, Inc. (Nasdaq: CEGE), which is headquartered in South San Francisco, CA. Ceregene's investors include Alta Partners, MPM Capital, Investor Growth Capital and Cell Genesys, as well as Hamilton BioVentures and California Technology Partners.
About Genzyme
One of the world's leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Since 1981, the company has grown from a small start-up to a diversified enterprise with more than 9,000 employees in locations spanning the globe and 2006 revenues of $3.2 billion. Genzyme has been selected by FORTUNE as one of the "100 Best Companies to Work for" in the United States.
With many established products and services helping patients in nearly 90 countries, Genzyme is a leader in the effort to develop and apply the most advanced technologies in the life sciences. The company's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant, and diagnostic testing. Genzyme's commitment to innovation continues today with a substantial development program focused on these fields, as well as immune disease, infectious disease, and other areas of unmet medical need.
Contacts: Jeffrey M. Ostrove, Ph.D.
President and CEO
Ceregene, Inc.
(858) 458-8808
Erin Emlock
Media
Genzyme Corporation
(617) 768-6923
Carol Miceli
Investors
Genzyme Corporation
(617) 768-6602
SOURCE Genzyme Corporation; Ceregene, Inc.
----------------------------------------------
Jeffrey M. Ostrove
Ph.D.
President and CEO of Ceregene
Inc.
+1-858-458-8808; or Media
Erin Emlock of Genzyme Corporation
+1-617-768-6923; or Investors
Carol Miceli of Genzyme Corporation
+1-617-768-6602
CNLG 2.10 Conolog Announces Final Test Approval by Major West Coast Utility for PDR2000-H and Related Systems for Exclusive Five-Year Sales Agreement
- Deliveries to Start in the Second Half of 2007 -
Jun 21, 2007 9:00:00 AM
SOMERVILLE, N.J., June 21 /PRNewswire-FirstCall/ -- Conolog Corporation (Nasdaq: CNLG), an engineering and design company that provides digital signal processing solutions to global electric utilities, announced today it has received final approval by a major North American utility for its PDR2000-H digital/analog systems and related ancillary systems for an exclusive five-year sales agreement for Conolog products.
Robert Benou, Chairman of Conolog said, "We are looking forward to supporting the Utility's protection needs in a timely fashion for the next five years and beyond."
Benou added, "The design versatility and dependability of our products provide ease of installation and years of uninterrupted service for existing fiber and analog phone lines.
About Conolog Corporation
Conolog Corporation is a provider of digital signal processing and digital security solutions to electric utilities worldwide. The Company designs and manufactures electromagnetic products to the military and provides engineering and design services to a variety of industries, government organizations and public utilities nationwide. The Company's INIVEN division manufactures a line of digital signal processing systems, including transmitters, receivers and multiplexers.
Contact: Conolog Corporation: Robert Benou, Chairman, 908/722-8081
Forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including, without limitation, continued acceptance of the Company's products, increased levels of competition, new products introduced by competitors, and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission. There can be no assurance that utilities will purchase any of our systems and the utility referred to in this release is not obligated to purchase any products from the Company.
SOURCE Conolog Corporation
----------------------------------------------
Robert Benou
Chairman of Conolog Corporation
+1-908-722-8081
CRMH 7.83 Majestic Insurance Writes More Than $4 Million in First-Dollar Guaranteed Workers' Compensation Since Receiving Approval in New Jersey
Jun 21, 2007 9:00:00 AM
SAN FRANCISCO, June 21 /PRNewswire-FirstCall/ -- Majestic Insurance Co. (Majestic), the U.S.-based primary insurance subsidiary of CRM Holdings, Ltd. ("CRMH") (Nasdaq: CRMH), announced today that it has bound more than $4 million in first-dollar premiums in New Jersey in less than three months of operations.
As of June 11, 2007, Majestic has written more than $4 million in New Jersey with an average premium size of $85,000. The company completed the necessary regulatory requirements to write first-dollar guaranteed cost workers' compensation insurance in New Jersey on March 22, 2007.
"Geographic diversification is a key component of our business strategy, and our expansion into New Jersey demonstrates our successful execution of this platform. Through our select broker network, we are eager to offer our expertise to targeted business sectors in New Jersey," said Mr. Daniel G. Hickey Jr., Chief Executive Officer of Majestic Insurance.
Majestic provides a market for better-than-average risks in a diversity of classifications that have been in business no less than three years. The company's initial focus in New Jersey will encompass contractors, transportation, healthcare, wholesale and retail, manufacturing, auto dealers, hospitality, physicians and dentists, colleges and universities, banks and other classes on a case-by-case basis.
"Since 1986, Majestic has been successfully combining superior performance in claim and risk control services with the ability to maintain long-term relationships with our policyholders and producers. Our brokers' and employees' commitment to these principles has earned Majestic the recognition as a leading business partner and service provider of workers' compensation insurance," Hickey said.
Currently, Majestic's rating plan is guaranteed cost with available schedule rating of +/- 10%, managed care credit of 10% to qualified employers and premium discount. Majestic also provides third-party claims administration to qualified customers. Future plans include offering loss sensitive plans.
About Majestic Insurance Company
Majestic Insurance Company is the U.S.-based primary insurance subsidiary of CRM Holdings, Ltd. and is rated A- (Excellent) by A.M. Best Company. Majestic provides primary workers' compensation insurance products throughout the U.S., primarily in California. Additional information on Majestic Insurance Company and its products and services can be found at http://www.majesticinsurance.com.
About CRM Holdings, Ltd.
CRM Holdings, Ltd. is a provider of workers' compensation insurance products. Its main business activities include providing fee-based management and other services to workers' compensation self-insured groups and, beginning in November 2006, the offering of a traditional workers' compensation insurance product. CRM provides its fee-based management services to self-insured groups in New York, California and Texas. It provides its traditional workers' compensation insurance coverage primarily to employers in California but also has active operations in Alaska, Arizona, Nevada, Oregon, Washington and, starting on April 1, 2007, New Jersey. CRM is a provider of reinsurance and excess workers' compensation coverage to the self-insured groups it manages as well as other qualified self-insured entities. Further information can be found on the CRM Web site at http://www.CRMHoldingsLtd.bm. Forward-Looking statements
This press release contains forward-looking statements within the meaning of federal securities law, including statements concerning plans, objectives, goals, strategies, projections of future events or performance and underlying assumptions (many of which are based, in turn, upon further assumptions). These statements are based on the Company's current expectations and projections about future events and are identified by terminology such as "may," "will," "should," "expect," "scheduled," "plan," "seek," "intend," "anticipate," "believe," "estimate," "aim," "potential," or "continue" or the negative of those terms or other comparable terminology.
All forward-looking statements involve risks and uncertainties. Although management believes that its plans, intentions and expectations are reasonable, the Company may not achieve its plans, intentions or expectations. There are or may be important factors that could cause actual results to differ materially from the forward-looking statements the Company makes in this document. Such risks and uncertainties are discussed in the Company's Form 10-K for the year ended December 31, 2006, and in other documents filed by the Company with the Securities and Exchange Commission. Management believes that these factors include, but are not limited to, the following:
-- The cyclical nature of the insurance and reinsurance industry;
-- Premium rates;
-- Investment results;
-- Regulatory changes;
-- The estimation of loss reserves and loss reserve development;
-- Reinsurance may be unavailable on acceptable terms, and the Company may
be unable to collect reinsurance;
-- The occurrence and effects of wars and acts of terrorism;
-- The effects of competition;
-- The possibility that the outcome of any litigation or arbitration
proceeding is unfavorable;
-- Failure to retain key personnel;
-- Economic downturns; and
-- Natural disasters.
These risks and others could cause actual results to differ materially from those expressed in any forward-looking statements made. The Company undertakes no obligation to update publicly or revise any forward-looking statements made.
CRMH-G
Contact Information:
Mark Collinson
CCG Investor Relations
10960 Wilshire Blvd., Ste. 2050
Los Angeles, CA 90024
(310) 231-8600 ext. 117
John Hernandez
Majestic Insurance
400 Second Street, Suite 200
San Francisco, CA 94107
(415) 222-9343
SOURCE Majestic Insurance Co.
----------------------------------------------
John Hernandez of Majestic Insurance
+1-415-222-9343; or Mark Collinson of CCG Investor Relations
+1-310-231-8600
ext. 117
for Majestic Insurance
KUN 5.86 China Shenghuo Pharmaceutical Holdings, Inc. Retains CCG Elite
Jun 21, 2007 9:00:00 AM
LOS ANGELES, Calif. and KUNMING, China, June 21 /Xinhua-PRNewswire- FirstCall/ -- China Shenghuo Pharmaceutical Holdings, Inc. ("China Shenghuo," "the Company") (Amex: KUN), a leading specialty pharmaceutical company engaged in researching, developing, manufacturing and marketing Sanchi-based medicinal products in the People's Republic of China ("PRC"), today announced it has retained CCG Elite to design and execute its investor relations campaign.
"China Shenghuo is one of the promising high-growth companies in China's emerging pharmaceutical market," said Crocker Coulson, President of CCG Elite. "The Company's historical revenue growth and capacity to develop and manufacture Sanchi for a variety of uses positions China Shenghuo as a very attractive investment vehicle that leverages the high growth rate of the traditional Chinese medicine industry in China."
In the first quarter of 2007, revenues were $4.3 million, while the Company's gross profit increased 11.4% year-over-year to $3.2 million. Gross margin was 73.6%, up from 63.9% in the first quarter of 2006. The Company expects gross margin to be approximately 60% for the full year 2007. Net income was $1.5 million, or $0.08 per diluted share, a 77.3% increase from $0.8 million, or $0.05 per diluted share, in the same quarter of 2006. The Company's stock began trading on the American Stock Exchange June 14, 2007, under the ticker symbol "KUN".
"China Shenghuo has strong brand recognition as we market our major Sanchi-based pharmaceutical products under the popular Lixuwang brand," said Mr. Lan Guihua, Chief Executive Officer and Chairman of China Shenghuo. "By emphasizing investment in scientific research and quality control, we have elevated the development of prescription and over-the-counter products based on traditional Chinese medicine practices."
Through its four subsidiaries, the Company has a diverse product portfolio, including pharmaceuticals, nutritional supplements and cosmetic products. The flagship product, Xuesaitong Soft Capsules, has been listed in the National Insurance Catalogue since 2005. China Shenghuo's integrated sales network spans more than 20 provinces in China.
The Company's state-of-the-art factories in the Kunming National Economy & Technology Developing District in mainland China have a combined production capacity of 1.5 billion soft capsules per year. China Shenghuo's advanced manufacturing procedures and effective quality control enable it to provide pharmaceutical products according to more stringent Western standards.
About CCG Elite
CCG Elite is uniquely positioned to provide an outsourced, high-level investor relations solution that combines in-depth understanding of Asia's corporate culture and economic scene and a direct pipeline into the leading funds and broker-dealers in the U.S. CCG Elite is a global, full-service investor relations agency with corporate headquarters in Los Angeles and offices in New York City, Newport Beach, Calif., Dallas, Texas, Hong Kong and Beijing. For further information, contact CCG Elite directly, or visit the Company's Web site at http://www.ccgelite.com .
About China Shenghuo Pharmaceutical Holdings, Inc.
Founded in 1995, China Shenghuo Pharmaceutical Holdings, Inc. ("China Shenghuo" or "the Company") is a leading specialty pharmaceutical company that focuses on the research, development, production and marketing of Sanchi-based medicinal products. Through its subsidiary, Kunming Shenghuo Pharmaceutical (Group) Co., Ltd ("Kunming Shenghuo"), it owns thirty-one SFDA (State Food and Drug Association)-approved medicines, including the flagship product Xuesaitong Soft Capsules, which has already been listed in the Insurance Catalogue. At present, Shenghuo incorporates a sales network of agencies and representatives throughout China, which markets Sanchi-based traditional Chinese medicine into 1,650 hospitals and 1,500 drug stores as prescription and OTC drugs primarily for the treatment of cardiovascular, cerebrovascular and peptic ulcer disease. The Company also exports medicinal products to Asian countries such as Indonesia, Thailand and Kyrgyzstan.
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: Any statements set forth herein that are not historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Such factors include, but are not limited to, the Company's reliance on one supplier for Sanchi, ability to develop and market new products, ability to establish and maintain a strong brand, continued maintenance of certificates, permits and licenses required to conduct business in China, protection of company's intellectual property rights, changes in the laws of the People's Republic of China that affect the company's operations, the company's ability to obtain all necessary government certifications and/or licenses to conduct the company's business and other factors detailed from time to time in the Company's filings with the United States Securities and Exchange Commission and other regulatory authorities. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
For more information, please contact:
China Shenghuo Pharmaceutical Holdings, Inc.
Ms. Gao Qionghua, CFO
Tel: +86-871-728-2608
Email: qionghua_kmsh@163.com
CCG Elite Investor Relations
Crocker Coulson, President
Tel: +1-646-213-1915 (New York)
Email: crocker.coulson@ccgir.com
SOURCE China Shenghuo Pharmaceutical Holdings, Inc.
----------------------------------------------
Ms. Gao Qionghua
CFO of China Shenghuo Pharmaceutical Holdings
Inc.
+86-871-728-2608
or qionghua_kmsh@163.com; or Crocker Coulson
President of CCG
+1-646-213-1915 (New York)
or crocker.coulson@ccgir.com
for China Shenghuo Pharmaceutical
VVUS 5.18 VIVUS Completes End of Phase 2 Meeting with the FDA for Qnexa, a Treatment for Obesity
FDA Accepts Phase 3 Development Plan for Qnexa in Obese Patients
Jun 21, 2007 8:30:00 AM
Copyright Business Wire 2007
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--
VIVUS, Inc. (NASDAQ: VVUS), a pharmaceutical company dedicated to the development and commercialization of novel therapeutic products, today announced that it has completed an end of phase 2 meeting with the United States Food and Drug Administration ("FDA") for Qnexa(TM). Qnexa is the company's investigational product candidate in development for the treatment of obesity.
The meeting with the FDA followed successful completion of the Qnexa phase 2 clinical program. The FDA reviewed Qnexa's current data package and clinical development plan and provided input on the company's overall plans for a phase 3 clinical development program and the plan to apply for a Special Protocol Assessment ("SPA") to support the registration of Qnexa in the United States as a treatment for obesity. As a result of the meeting with the FDA, the phase 3 program will be designed to dose patients for 56 weeks (inclusive of a 4-week titration period) and will enroll approximately 4,500 patients in the placebo-controlled pivotal studies. The company expects to study obese patients (body mass index (BMIgreater than30) and obese patients with associated co-morbidities (BMIgreater than27), such as type 2 diabetes, hypertension and dislipidemia.
The primary endpoint in the obesity studies will be the proportion of patients who lose at least 5% of their body weight, as well as a range of secondary endpoints including absolute weight loss and the proportion of patients who lose over 10% of their body weight compared to placebo. The company is currently preparing an SPA request for submission. Safety will be evaluated in all studies.
"After our meeting with the FDA and the comments made by the FDA Advisory Panel meeting on rimonabant, we believe we have the benefit of the most current thinking on clinical safety and efficacy requirements for approval of obesity products," said Leland F. Wilson, president and CEO of VIVUS. "The FDA was responsive during the review and subsequent discussion of the Qnexa data package. We believe the phase 3 development program is on track and are looking forward to enrolling subjects in the pivotal studies this fall."
The company previously announced positive phase 2 clinical study results with Qnexa in May 2006. The study, which was conducted by Duke University Medical Center, was a double-blind, randomized, placebo controlled trial. Findings from the study included:
-- Over 50% of patients on Qnexa experienced 10% or more total
body weight loss in 24 weeks
-- Patients on Qnexa achieved a placebo-adjusted weight loss of
20.3 pounds at week 24 (based upon intent to treat)
-- Weight loss with Qnexa had not plateaued by 24 weeks
-- Qnexa was well tolerated. Four patients (8%) dropped out of
the Qnexa study arm for any reason, versus 19 patients (38%)
on placebo.
This trial involved 200 subjects; 159 women and 41 men with an average age of 40 and a mean body mass index (BMI) of 38. Improvements in secondary endpoints including reduction in waist circumference and reduction in blood pressure and cholesterol levels were also reported in the phase 2 study.
About Qnexa
Qnexa is a proprietary pharmaceutical treatment that incorporates low doses of active ingredients from two previously FDA approved products (phentermine and topiramate). By combining the activity of each of these compounds, Qnexa is designed to simultaneously address excessive appetite and high threshold for satiety, the two main mechanisms that impact eating behavior. Qnexa is subject to U.S. and International patents.
About VIVUS
VIVUS, Inc. is a pharmaceutical company dedicated to the development and commercialization of novel therapeutic products. The current portfolio includes investigational products addressing obesity and sexual health. VIVUS has three products that are positioned to enter Phase 3 clinical trials, and one product currently under NDA review by the FDA. The pipeline includes: Qnexa(TM), for which a phase 2 study has been completed for the treatment of obesity; Testosterone MDTS(R), for which a phase 2 study has been completed for the treatment of Hypoactive Sexual Desire Disorder (HSDD); EvaMist(TM), for which a phase 3 study has been completed and an NDA submitted for the treatment of menopausal symptoms, and on May 15, 2007, the EvaMist assets were sold to KV Pharmaceutical Company; and avanafil, for which a phase 2 study has been completed for the treatment of erectile dysfunction (ED). MUSE(R) is approved and currently on the market for the treatment of ED. For more information on clinical trials and products, please visit the company's web site at www.vivus.com.
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimated" and "intend," among others. These forward-looking statements are based on VIVUS' current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; uncertainties of patent protection and litigation; uncertainties of government or third party payer reimbursement; reliance on sole source suppliers; limited sales and marketing efforts and dependence upon third parties; risks related to the development of innovative products; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that the EvaMist NDA submission will be approved in a timely basis, or at all. There are no guarantees that future clinical studies discussed in this press release will be initiated, completed or successful or that any product will receive regulatory approval for any indication or prove to be commercially successful. VIVUS does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in VIVUS' Form 10- K for the year ended December 31, 2006 and periodic reports filed with the Securities and Exchange Commission.
Source: VIVUS, Inc.
----------------------------------------------
VIVUS
Inc.
Timothy E. Morris
650-934-5200
Chief Financial Officer
or
The Trout Group
Ian Clements
(SF) 415-392-3385
Brian Korb
(NYC) 646-378-2923
II 4.40 Ivivi to Release Fiscal 2007 and Fourth Quarter Results and Hold Conference Call on June 28, 2007
Jun 21, 2007 8:30:00 AM
Copyright Business Wire 2007
NORTHVALE, N.J.--(BUSINESS WIRE)--
Ivivi Technologies, Inc. (AMEX: II), a leader in non-invasive, electrotherapeutic technologies, today announced that management will discuss the Company's results for its fiscal year and fourth quarter ended March 31, 2007, during a conference call scheduled for Thursday, June 28, 2007 at 4:30 pm ET. The Company's financial results for fiscal 2007 and fourth quarter 2007 are scheduled to be released after the market closes on June 28, 2007 and prior to the conference call.
Shareholders and other interested parties may participate in the conference call by dialing (877) 407-0782 approximately 5 to 10 minutes before the beginning of the call. International callers should dial (201) 689-8567. If you are unable to participate, a replay of the call will be available until midnight on July 12, 2007 by dialing (877) 660-6853 and using pass code # 286 and conference ID # 246241. International callers should dial (201) 612-7415 and use the pass codes listed above. The call will also be broadcast live on the Internet at www.InvestorCalendar.com and on the Investor Relations section of the Company's website www.ivivitechnologies.com. An archive of the call will also be available on the Company's website.
About Ivivi Technologies, Inc.
Based in Northvale, NJ, Ivivi Technologies, Inc. is a medical technology company focusing on designing, developing and commercializing its proprietary electrotherapeutic technology platform. Ivivi's research and development activities are focused specifically on pulsed electromagnetic field, or PEMF, technology, which, by creating a therapeutic electrical current in injured soft tissue, stimulates biochemical and physiological healing processes to help repair the injured tissue and reduce related pain and inflammation. The Company's Electroceuticals(TM) have been used in non-invasive treatments for a wide array of conditions, including chronic wounds, pain and edema following plastic and reconstructive surgery and chronic inflammatory disorders.
Source: Ivivi Technologies, Inc.
----------------------------------------------
Investor Relations:
Cameron Associates
Alison Ziegler or Lester Rosenkrantz
212-554-5469
Alison@cameronassoc.com
or
Media
Deanne Eagle
212-554-5463
Deanne@cameronassoc.com
TBUS 2.52 Digital Recorders, Inc. Announces $500,000 Order for TwinVision(R) All-LED Sign Systems
Jun 21, 2007 8:30:00 AM
Copyright Business Wire 2007
DALLAS--(BUSINESS WIRE)--
Digital Recorders, Inc. (DRI) (NASDAQ: TBUS), a digital communications technology leader in the domestic and international public transportation and transit security markets, announced today that its TwinVision na, Inc. subsidiary in Durham, N.C., has received a product order valued at approximately $500,000 from the Capital District Transit Authority (CDTA) in Albany, N.Y.
"The CDTA is upgrading portions of its existing passenger transit fleet's communications products. Soon, the CDTA's reliance upon older technology such as front- and side-roller curtain signs and rear flip-dot signs will be a thing of the past. Instead, the CDTA's bus vehicle fleet will be retrofitted with the TwinVision(R) amber all-LED electronic destination sign system -- a solid-state, technologically innovative product. This will improve the reliability and readability of the CDTA's route communications, as well as assist the CDTA in ensuring its compliance with the Americans with Disabilities Act. Since there are no moving parts in this product, the CDTA's maintenance costs also will be reduced. Our TwinVision(R) products improve the flow of people through the transit experience. As such, our products contribute to energy efficiency, help reduce roadway congestion, and support the need to reduce fossil fuel consumption. Indeed, our TwinVision(R) products and services foster environmental stewardship," David L. Turney, the Company's Chairman, President, and Chief Executive Officer, said.
Management anticipates that delivery will conclude in the last half of 2007.
ABOUT THE TWINVISION NA, INC. SUBSIDIARY
Established in 1996, TwinVision na, Inc. designs, manufactures, sells, and services TwinVision(R) electronic destination sign systems used on public transit vehicles. With leading edge technology, the subsidiary was the first established U.S. supplier to bring amber- and multi-colored, solid-state displays to the U.S. market, innovatively replacing the decades' old flip-dot, bulb, and ballast technology. For more information, go to www.twinvisionsigns.com.
ABOUT THE COMPANY
DRI is a digital communications technology leader in the domestic and international public transportation and transit security markets. Our products include: TwinVision(R) and Mobitec(R) electronic destination sign systems, Talking Bus(R) voice announcement systems, Digital Recorders(R) Internet-based passenger information and automatic vehicle location/monitoring systems, and VacTell(TM) video actionable intelligence systems. Our products help increase the mobility, flow, safety, and security of people who rely upon transportation infrastructure around the globe. Using proprietary hardware and software applications, our products provide easy-to-understand, real-time information that assists users and operators of transit bus and rail vehicles in locating, identifying, boarding, tracking, scheduling, and managing those vehicles. Our products also aid transit vehicle operators in their quest to increase ridership and reduce fuel consumption, as well as to identify and mitigate security risks on transit vehicles. Positioned not only to serve and address mobility, energy conservation, and environmental concerns, our products also serve the growing U.S. Homeland Security market. For more information about the Company and its operations worldwide, go to www.digrec.com.
FORWARD-LOOKING STATEMENTS
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. In particular, statements concerning the timing and amount of the orders, the expected delivery dates, our ongoing relationship with the CDTA, the expected demand for our products and their ability to help the environment, as well as any statement, express or implied, concerning future events or expectations is a forward-looking statement. Use of words such as "expect," "fully expect," "expected," "appears," "believe," "plan," "anticipate," "would," "goal," "potential," "potentially," "range," "pursuit," "run rate," "stronger," "preliminarily," etc., is intended to identify forward-looking statements that are subject to risks and uncertainties, including risks and uncertainties pertaining to the timing and amount of the orders, the expected delivery dates, our ongoing relationship with the CDTA, the expected demand for our products and their ability to help the environment, as well as other risks and uncertainties as set forth in our Annual Report on Form 10-K filed March 28, 2007, particularly those identified in Risk Factors Affecting Our Business. There can be no assurance that any expectation, express or implied, in a forward-looking statement will prove correct or that the contemplated event or result will occur as anticipated.
Source: Digital Recorders, Inc.
----------------------------------------------
Veronica B. Marks
Manager
Corporate Communications
Digital Recorders
Inc.
Phone: (214) 378-4776
Fax: (214) 378-8437
E-Mail: veronicam@digrec.com
BRCD 8.29 Brocade Among Top Finalists for the 2007 Microsoft Partner of the Year Award in Advanced Infrastructure Solutions, Storage Solutions
Microsoft Windows-Based File Area Network (FAN) Solution, Brocade StorageX, Recognized for Its Ability to Improve Enterprise-Wide File Data Management
Jun 21, 2007 8:22:00 AM
SAN JOSE, Calif., June 21 /PRNewswire-FirstCall/ -- Brocade(R) (Nasdaq: BRCD), the leader in networked storage solutions that help enterprises connect and manage their information, today announced that it has been selected as a finalist for Microsoft Corp.'s Partner of the Year Award in Advanced Infrastructure Solutions, Storage Solutions. Winners for the 2007 Microsoft Partner Program Awards, which recognize top Microsoft Partners delivering market-leading, Microsoft-based solutions, will be announced July 11 in Denver, Colorado at the Microsoft Worldwide Partner Conference.
"Brocade is honored to be included among the elite list of finalists for the Microsoft Partner of the Year Awards Program," said Tom Buiocchi, Brocade Vice President of Worldwide Marketing. "With companies continually generating Windows-based data that must be managed, stored, and protected, Brocade's tight integration with Microsoft native technologies enables its FAN suite of products, including Brocade StorageX(R), to fit seamlessly into customers' existing Windows-based infrastructures while solving their most critical file data management needs."
Awards will be presented in a number of categories, with winners chosen from a pool of more than 1,800 entrants worldwide. The Advanced Infrastructure Solutions, Storage Solutions Partner of the Year Award honors partners that have storage infrastructure practices in design and/or implementation of various storage solutions to solve customers' issues with data growth in their Windows environments. Customers are looking to Microsoft technologies to meet the growing demands on their storage infrastructure due to compliance requirements and massive year-over-year data growth. The winning partner will have developed and deployed cost-effective storage solutions that integrated Windows Server storage technologies or Windows Storage Server in customer environments.
"We have a diverse and talented partner ecosystem that each year raises the bar in the design and deployment of customer solutions built on Microsoft technologies," said Allison L. Watson, Corporate Vice President, Microsoft Worldwide Partner Group. "We are pleased to recognize Brocade as one of our partners leading the field in this category."
About Brocade StorageX
Brocade StorageX is an integrated suite of applications that logically aggregate distributed file data across heterogeneous storage environments and across CIFS- and NFS-based file systems while providing policies to automate data management functions. Brocade StorageX supports tasks in key areas such as:
-- Centralized network data management
-- Data migration and consolidation
-- Disaster recovery and business continuity
-- Branch office data management
-- Information Lifecycle Management (ILM)
-- Storage optimization
-- Data classification and reporting
Brocade StorageX provides administrators with powerful policies to efficiently manage distributed file data for an enterprise. Moreover, it directly addresses the needs of both administrators and users by increasing data availability, optimizing storage capacity, and simplifying storage management-all leading to significantly lower costs for enterprise data infrastructures. For more information about Brocade StorageX, visit the Brocade Web site at http://www.brocade.com/products/fan/storagex.jsp.
About Brocade
Brocade is the leading provider of networked storage solutions that help organizations connect, share, and manage their information. Organizations that use Brocade products and services are better able to optimize their IT infrastructures and ensure compliant data management. For more information, visit the Brocade Web site at http://www.brocade.com or contact the company at info@brocade.com.
Brocade, the Brocade B-wing logo, Fabric OS, File Lifecycle Manager, MyView, Secure Fabric OS, SilkWorm, and StorageX are registered trademarks and the Brocade B-weave symbol and Tapestry are trademarks of Brocade Communications Systems, Inc., in the United States and/or in other countries. FICON is a registered trademark of IBM Corporation in the U.S. and other countries. All other brands, products, or service names are or may be trademarks or service marks of, and are used to identify, products or services of their respective owners.
SOURCE Brocade
----------------------------------------------
Michelle Leach
Media Relations
+1-408-333-5319
mleach@brocade.com
or Darby Dye
Investor Relations
+1-408-333-5752
ddye@brocade.com
both of Brocade; or Ian Yellin of Ogilvy PR
+1-415-677-2714
ian.yellin@ogilvypr.com
for Brocade
WPTE 4.21 Bluff Europe Magazine Announces 'Poker in the Park' Sponsored by World Poker Tour(R)
An Afternoon of Poker Fun-in-the-Sun to Be Held in Leicester Square, July 6th
Jun 21, 2007 8:11:00 AM
Copyright Business Wire 2007
LONDON--(BUSINESS WIRE)--
Bluff Europe magazine, Europe's premier poker publication, is celebrating summer and its crowning of London as "Europe's #1 Poker City" by holding an afternoon of poker with the World Poker Tour(R) (WPT) in the heart of London.
"Poker in the Park" will be held in Leicester Square Park on Friday, July 6th, from 12:00pm to 4:00pm. Bluff Europe and WPT will be holding 'Learn to Play' and 'Play for-Fun' tournaments for poker enthusiasts and players of all skills and backgrounds.
The event, presented by Bluff Europe and sponsored by the World Poker Tour, is open to all visitors over 18 years of age. Visitors who choose to play might find themselves across the table from actress Mimi Rogers, who is also a WPT Board member and poker enthusiast. WPT president, founder and CEO, Steve Lipscomb, will also attend the event. In addition, World Poker Tour poker gift packages will be given to the first 1,000 visitors.
"We are pleased to be a part of this celebration as London is named the #1 poker capitol in Europe," said Lipscomb. "World Poker Tour was at the forefront of the global television poker phenomenon, which helped bring the poker boom to London. We are honoured to have played a part in this great city's rich history."
To mark the magazine's naming of London as Europe's No.1 poker destination, a plaque will be awarded to the Mayor of London, congratulating the city for its services to the poker community.
"'Poker in the Park' is an opportunity for people who have an interest in the game to come out and play for free in a fun, friendly environment, and to find out what all the excitement is about," said Michael Caselli, editor-in-chief of Bluff Europe. "People are really beginning to see that poker is a game of skill and intellect and that tournament poker is about mental fortitude - it really is about the sport of poker. The event is also a celebration of the London poker boom which punctuates London as one of the most exciting places to be right now."
ABOUT BLUFF EUROPE
Bluff Europe is Europe's most widely read poker publication, aimed squarely at the poker enthusiast. The magazine is distributed through European card rooms and poker clubs as well as on newsstands in the UK, Germany and Scandinavia. Regular contributors include Phil Laack, Roy Brindley, Hollywood Star turned poker pro - Jennifer Tilly and a host of other poker professionals from the UK, Europe and the USA.
Bluff Europe magazine is the first magazine to be available by subscription through SMS. Poker enthusiasts in the UK can subscribe by texting POKER to 60155. www.bluffeurope.com
ABOUT WPTE
WPT Enterprises, Inc. (Nasdaq:WPTE) is a company engaged in the creation of internationally branded entertainment and consumer products driven by the development, production, and marketing of televised programming based on gaming themes. WPTE is the creator of the World Poker Tour(R), a television show based on a series of high-stakes poker tournaments that airs on the Travel Channel in the United States and is scheduled to begin broadcasting on GSN in early 2008. WPT is licensed for broadcast globally. WPTE also operates a real-money online gaming website, www.wptonline.com, which prohibits wagers from players in the U.S. and other restricted jurisdictions. WPTE currently licenses its brand to companies in the business of poker equipment and instruction, apparel, publishing, electronic and wireless entertainment, DVD/home entertainment, casino games, and giftware. The company is also engaged in the sale of corporate sponsorships. For show information, tools for improving poker play, and other WPT news, fans may log on to www.worldpokertour.com. WPT Enterprises, Inc. is a majority owned subsidiary of Lakes Entertainment, Inc. (Nasdaq:LACO). Photos and media information can be found online at: www.worldpokertour.com/media
Source: Bluff Europe
----------------------------------------------
Lyceum Media for Bluff Europe
Melissa Ross
+44 (0) 207 953 4026
Melissa@lyceummedia.com
ISPH 5.87 Inspire Announces Webcast of Presentation at Jefferies Healthcare Conference
Jun 21, 2007 7:30:00 AM
Copyright Business Wire 2007
DURHAM, N.C.--(BUSINESS WIRE)--
Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today that Thomas R. Staab, II, Chief Financial Officer and Treasurer, and Donald J. Kellerman, Pharm.D., Senior Vice President, Development, will present at the Jefferies Healthcare Conference on Thursday, June 28, 2007 at 1:30 pm ET in New York City.
The webcast of the presentation will be available on Inspire's web site at www.inspirepharm.com. An archived version of the webcast presentation will also be available through this link for a limited time following the conference.
About Inspire
Inspire is a biopharmaceutical company dedicated to discovering, developing and commercializing prescription pharmaceutical products in disease areas with significant commercial potential and unmet medical needs. Inspire employs a U.S. sales force for the promotion of AzaSite(TM) (azithromycin ophthalmic solution) 1% for bacterial conjunctivitis, Elestat(R) (epinastine HCI ophthalmic solution) 0.05% for allergic conjunctivitis and Restasis(R) (cyclosporine ophthalmic emulsion) 0.05% for dry eye. Inspire is focused on the therapeutic areas of ophthalmology and respiratory/allergy, and is developing products for dry eye, cystic fibrosis, allergic rhinitis and glaucoma. Elestat and Restasis are trademarks owned by Allergan, Inc. AzaSite is a trademark owned by InSite Vision Incorporated. For more information, visit www.inspirepharm.com.
Source: Inspire Pharmaceuticals, Inc.
----------------------------------------------
Inspire Pharmaceuticals
Inc.
Investor Contact:
Jenny Kobin
919-941-9777
Ext. 219
VP
Investor Relations and Corporate Communications
or
BMC Communications
Media Contact:
Dan Budwick
212-477-9007
Ext. 14
SUPR 10.24 Superior Bancorp Announces Stock Repurchase Program and Trust Preferred Refinancing
Jun 21, 2007 7:00:00 AM
BIRMINGHAM, Ala., June 21 /PRNewswire-FirstCall/ -- Superior Bancorp (Nasdaq: SUPR), the holding company for Superior Bank, today announced that its Board of Directors has authorized, beginning on or after August 2, 2007, the purchase by the Company of up to one million shares of the Company's outstanding common stock. The shares may be purchased in open market, negotiated or block transactions. The Company does not intend to repurchase any shares from its management team or other insiders. This stock buyback program does not obligate the Company to acquire any specific number of shares and may be suspended or discontinued at any time. As of March 31, 2007, the Company had approximately 34.7 million shares of its common stock outstanding. After completion of its merger with People's Community Bancshares, Inc., expected to occur during July 2007, the Company will have approximately 41.1 million shares outstanding.
"We believe that the current share price does not accurately reflect Superior's long-term value and therefore represents an excellent investment opportunity for both the Company and our shareholders," said Stan Bailey, Chairman and CEO. "We believe this initiative is an effective use of our capital. In addition, the strength of our balance sheet enables us to simultaneously execute this program while still retaining significant flexibility to achieve our long-term growth strategies and build greater shareholder value," concluded Bailey.
Superior's Board also authorized the refinancing of the approximately $16 million TBC Capital Statutory Trust III trust preferred securities during the third quarter of 2007. The Company is calling those securities for redemption effective July 25, 2007 at a redemption price equal to 106.15% of par. The Company expects to issue up to $22 million of new trust preferred securities in a private placement and to use a portion of the proceeds of such new trust preferred securities to redeem the outstanding securities. The Company is in the process of negotiating the terms of such new trust preferred securities. The remaining proceeds from the issuance of the new trust preferred securities will be available for use in the stock repurchase program or for other corporate purposes. The Company expects to incur an earnings charge of approximately $925,000 net of tax, or $.02 per share, in the third quarter of 2007 relating to the redemption of the outstanding trust preferred securities. Nothing in this press release constitutes an offer to sell, or the solicitation of an offer to buy, the proposed new trust preferred securities.
About Superior Bancorp
Superior Bancorp is a $2.4 billion thrift holding company headquartered in Birmingham, Alabama. The principal subsidiary of Superior Bancorp is Superior Bank, a southeastern community bank with 60 branches -- 38 locations throughout the state of Alabama and 22 locations in Florida. In addition, Superior Bank currently has 11 new branches planned for Northeast Alabama and Florida during 2007 and 2008.
Superior Bank also has loan production offices in Montgomery, Alabama and Tallahassee, Marianna and Panama City, Florida, and operates 19 consumer finance offices in Northeast Alabama as First Community Credit and Superior Financial Services.
Upon completion of the recently announced merger with People's Community Bancshares, Inc., Superior Bank will become a $2.8 billion community bank with 63 banking offices from Huntsville, Alabama to Venice, Florida.
Statements in this document that are not historical facts, including, but not limited to, statements concerning future operations, results or performance, are hereby identified as "forward-looking statements" for the purpose of the safe harbor provided by Section 21E of the Securities Exchange Act of 1934 and Section 27A of the Securities Act of 1933. Superior Bancorp cautions that such "forward-looking statements," wherever they occur in this document or in other statements attributable to Superior Bancorp are necessarily estimates reflecting the judgment of Superior Bancorp's senior management and involve a number of risks and uncertainties that could cause actual results to differ materially from those suggested by the "forward- looking statements." Such "forward-looking statements" should, therefore, be considered in light of various important factors set forth from time to time in Superior Bancorp's reports and registration statements filed with the SEC. While it is impossible to list all such factors that could affect the accuracy of such "forward-looking statements," some of those factors include: general economic conditions, especially in the Southeast; the performance of the capital markets; changes in interest rates, yield curves and interest rate spread relationships; changes in accounting and tax principles, policies or guidelines; changes in legislation or regulatory requirements; changes in the competitive environment in the markets served by Superior Bancorp; changes in the loan portfolio and the deposit base of Superior Bancorp; and the effects of natural disasters such as hurricanes.
Superior Bancorp disclaims any intent or obligation to update "forward- looking statements."
More information on Superior Bancorp and its subsidiaries may be obtained over the Internet, http://www.superiorbank.com, or by calling 1-877-326-BANK (2265).
SOURCE Superior Bancorp
----------------------------------------------
Tom Jung
Executive Vice President of Superior Bancorp
+1-205-327-3547
CREAF 4.98 Creative Introduces the ZEN Stone Plus Using the Same Cool Style and Colors of the ZEN Stone with Exciting New Features
With a Vibrant Screen, 2GB Memory, the ZEN Stone Plus MP3 Player Holds Up To 500 Songs, Features FM Radio, Clock, Stopwatch, Voice Recording and More
Jun 21, 2007 7:00:00 AM
MILPITAS, Calif., June 21 /PRNewswire-FirstCall/ -- Creative (Nasdaq: CREAF), a worldwide leader in digital entertainment products, today introduced an exciting new choice in MP3 players to complement the recent introduction of the ZEN(TM) Stone MP3 player. The new Creative ZEN Stone Plus is a featherweight 2GB MP3 player with a rich selection of features, including FM radio, voice recording and more. The Creative ZEN Stone Plus will be available in July at Amazon.com, Buy.com, Dell.com, Fry's Electronics, Frys.com, J&R, Newegg.com, Target.com, WalMart.com and us.creative.com for the great low price of only US$69.99.
Like the ZEN Stone, the Creative ZEN Stone Plus comes in six high-gloss colors: black, white, red, blue, pink and green, and it features a smooth contoured design, so it feels naturally comfortable in your hand.
"On May 3 we introduced a huge new market for MP3 players with the introduction of the ZEN Stone, the tiny, featherweight 1GB MP3 player priced at only $39.99," said Sim Wong Hoo, chairman and CEO of Creative. "Now with the ZEN Stone Plus, we give consumers another great choice. For just $69.99, they can have 2GB of memory with a vibrant color screen for access to all their favorite FM radio stations, plus a built-in microphone for voice recording. There's even a clock, stopwatch, and customizable equalizer settings."
There is no driver installation necessary to add music to the ZEN Stone Plus. Just drag and drop up to 500 songs* and choose "Play" or "Random" and listen to up to 9.5 hours of your favorite songs from a single charge of the built-in battery.
You can personalize the Creative ZEN Stone Plus with attractive silicone skins that include a clip and are available in five different colors. A sporty armband that comes with a skin is also available, a wristband that doubles as a watch band for the clock and stopwatch, and a fashionable keychain with a tiny case that carries the player.
The Creative TravelSound ZEN Stone is the perfect portable speaker system for the Creative ZEN Stone or Creative ZEN Stone Plus, for frequent travelers and music lovers alike. Its smooth polished curves and contoured design allow the Creative TravelSound ZEN Stone to rest comfortably in your hands when you are on the move. The design includes a retractable stand that lets you place the Creative TravelSound ZEN Stone on virtually any flat surface and listen to your favorite music from your docked Creative ZEN Stone or Creative ZEN Stone Plus.
Using micro drivers, this lightweight versatile portable speaker system provides crystal clear sound for more than 20 hours of great entertainment anywhere you go, powered by just two AAA alkaline batteries. You can even listen to your music at lower volume without batteries as the speaker can operate without the power amplifier. The Creative TravelSound ZEN Stone is priced at only US$39.99.
For more information about the Creative ZEN Stone Plus visit http://www.us.creative.com.
*Based on MP3 format encoded at 128kbps; the ZEN Stone Plus can also hold up to 1000 WMA songs encoded at 64kbps.
About Creative
Creative (Nasdaq: CREAF) is a worldwide leader in digital entertainment products. Famous for its Sound Blaster(R) sound cards and for launching the multimedia revolution, Creative is now driving digital entertainment on the PC platform with products like its highly acclaimed ZEN MP3 and portable media players. Creative's innovative hardware, proprietary technology, applications and services leverage the Internet, enabling consumers to experience high-quality digital entertainment -- anytime, anywhere.
This announcement relates to products launched in the United States. Availability is subject to change without notice and may differ elsewhere in the world according to local factors and requirements. Sound Blaster and ZEN are trademarks or registered trademarks of Creative Technology Ltd. in the United States and/or other countries.
SOURCE Creative
----------------------------------------------
Phil O'Shaughnessy of Creative Labs
Inc.
+1-408-546-6773
poshaughnessy@creative.com
MRGE 6.52 Merge Healthcare Announces Date for Second Quarter 2007 Earnings Release
Jun 21, 2007 7:00:00 AM
MILWAUKEE, June 21 /PRNewswire-FirstCall/ -- Merge Technologies Incorporated, doing business as Merge Healthcare (Nasdaq: MRGE; TSX: MRG), a leading provider of medical imaging software and services, today announces the planned timing of its communications on its second quarter 2007 financial results.
(Logo: http://www.newscom.com/cgi-bin/prnh/20030430/MRGELOGO)
On Wednesday, August 8, 2007, after the market close, Merge Healthcare will publish a press release announcing its financial results as of and for the three months ended June 30, 2007. The Company will hold an Earnings Conference Call on Thursday, August 9, 2007, beginning at 9:00 AM Central / 10:00 AM Eastern. Details on the dial-in and web cast are listed below.
To access the live call, dial +1-800-639-2197 or +1-706-634-2159. Reference Conference ID Number: 4418304. The call may also be accessed via web cast, either as the live event or as an archived event, by going to: http://www.videonewswire.com/event.asp?id=40514.
For additional details and replay information, please visit our website at: http://www.merge.com/CORP/investorrelations/confcalllist.asp
Merge Healthcare is a market leader in the development and delivery of medical imaging and information management software and services. Our innovative software solutions use leading-edge imaging software technologies that accelerate market delivery for our OEM customers, while our end-user solutions improve our customers' productivity and enhance the quality of patient care they provide. For additional information, visit our website at http://www.mergehealthcare.com.
SOURCE Merge Healthcare
----------------------------------------------
Melanie Gretzon
Director
Corporate Services of Merge Healthcare
+1-414-977-4000
ir@mergehealthcare.com
Q 9.56 Qwest Wireless Offers Smartphone with Advanced Data and Browsing Capabilities
MOTO Q Handset Offers Mobile Access to E-mail, Internet, Gaming and Music in Ultra-sleek Design
Jun 21, 2007 7:00:00 AM
Copyright Business Wire 2007
DENVER--(BUSINESS WIRE)--
Qwest Communications International Inc. (NYSE: Q) today announced that Qwest Wireless(R) now offers a Motorola wireless handset with the ultimate in mobile access to data and voice service. The MOTO Q(TM) smartphone handset supports Web browsing at up to broadband-like speeds(1), access to e-mail accounts with real-time mail delivery(1), and camera functions. The handset is slim and sleek, yet sports a sizable 2.4-inch display screen for vivid color viewing of all multimedia and downloads(1). To view images of the new handset, visit www.qwest.com/wireless.
The MOTO Q holds up to eight e-mail message inboxes(1) and includes optional expandable memory up to two gigabits for the on-the-go user with a massive appetite for data. The handset offers high speeds when accessing Sprint Power Vision(SM) network coverage to download content(1), and features document viewing services(1) so users can view spreadsheets, presentations and other documents.
"Qwest Wireless is excited to offer customers a mobile gateway to their personal and professional information in one convenient device," said Frank Simanson, vice president of product management for Qwest. "The MOTO Q gives tech-savvy customers the ability to live life outside the home or office and still have access to the Internet, e-mail, music, photos and more at their fingertips."
Qwest Wireless network services are provided on the Sprint(R) Nationwide PCS Network. The new handset is currently available at a discounted price with a one- or two-year Qwest Wireless contract for eligible customers. New and existing customers can visit a Qwest retail store, visit www.qwest.com/wireless or call 1-800-244-1111 for more information.
About Qwest
Qwest offers a unique and powerful combination of managed voice and data solutions for businesses, government agencies and consumers - locally and throughout the country. Customers coast to coast are turning to Qwest's industry-leading national fiber optic network and its Spirit of Service for quality products and superior customer experience. Qwest is a participant in Networx, the largest communications services contract in the world, to provide leading-edge voice, data and video services. For more information on Qwest, and its various operating subsidiaries, please go to www.qwest.com. For information about the products and services Qwest is offering in the Networx contract, visit www.gsanetworx.com.
(1) Airtime, data charges, and/or additional charges may apply. Wireless e-mail functionality requires an e-mail account with wireless server capabilities.
Source: Qwest Communications International Inc.
----------------------------------------------
Qwest Communications International Inc.
Media Contact:
Leigh Picchetti
303-965-1414
leigh.picchetti@qwest.com
or
Investor Contact:
Stephanie Comfort
800-567-7296
IR@qwest.com
NRMX 7.28 Neurochem receives third recommendation from European Data Safety Monitoring Board to continue Phase III clinical trial for tramiprosate (ALZHEMED(TM))
Jun 21, 2007 7:00:00 AM
LAVAL, QC, June 21 /PRNewswire-FirstCall/ - Neurochem Inc. (NASDAQ: NRMX; TSX: NRM) announces that it has received a third recommendation from the European Data Safety Monitoring Board (DSMB) to continue its ongoing European Phase III clinical trial for tramiprosate (ALZHEMED(TM)), Neurochem's investigational product candidate for the treatment of Alzheimer's disease (AD).
The DSMB is made up of independent clinical experts who monitor and evaluate the safety of patients taking part in the tramiprosate (ALZHEMED(TM)) Phase III clinical trial. In Europe, this third recommendation by the DSMB members was based on their recent review of the available safety data from 747 patients who have been on study medication for an average of 5.7 months.
Neurochem is progressing with its multicenter, randomized, double-blind, placebo-controlled, three-armed and parallel-designed, 18-month Phase III clinical trial for tramiprosate (ALZHEMED(TM)) in Europe. This clinical trial was initiated in September 2005. More than 950 mild-to-moderate AD patients at close to 70 sites across ten European countries are already enrolled in this clinical trial. The recruitment will continue at least until after top-line results of the North American study are released. With respect to the completed Phase III North American clinical trial for tramiprosate (ALZHEMED(TM)), Neurochem received during the course of the clinical trial five recommendations from the North American DSMB to continue the study.
Tramiprosate (ALZHEMED(TM)) is a small, orally-administered molecule known as an amyloid (B) antagonist, which crosses the blood-brain-barrier, binds to soluble A(B) peptide and interferes with the amyloid cascade that is associated with amyloid deposition and the toxic effects of A(B) peptide in the brain.
About Alzheimer's Disease
AD is a leading cause of death in older people. The disease is characterized by the progressive death of nerve cells in the brain, making it difficult for the brain's signals to be transmitted properly. A person with AD experiences problems with memory, judgment, thinking, and eventually with motor functions, all of which make it difficult for the person to participate in daily activities.
According to the U.S. Alzheimer Association (2007), there are now more than five million people in the United States living with Alzheimer's disease. This number includes 4.9 million people aged 65 and older. It also includes at least 200,000 individuals younger than 65 with early-onset Alzheimer's disease. It is estimated that by 2010, there will be 454,000 new cases of AD a year, 615,000 new cases by 2030 and 959,000 new cases by 2050. In the United States, the direct and indirect costs of AD and other dementias amount to more than US$148 billion annually.
About Neurochem
Neurochem Inc. is focused on the development and commercialization of innovative therapeutics to address critical unmet medical needs. Eprodisate (KIACTA(TM)) is currently being developed for the treatment of Amyloid A (AA) amyloidosis, and is under regulatory review for marketing approval by the U.S. Food and Drug Administration, the European Medicines Agency and Swissmedic. Tramiprosate (ALZHEMED(TM)), for the treatment of Alzheimer's disease, has completed a Phase III clinical trial in North America and is currently in a Phase III clinical trial in Europe, while tramiprosate (CEREBRIL(TM)), for the prevention of Hemorrhagic Stroke caused by Cerebral Amyloid Angiopathy, has completed a Phase IIa clinical trial.
To Contact Neurochem
For additional information on Neurochem and its drug development programs, please call the North American toll-free number 1 (877) 680-4500 or visit our Web site at www.neurochem.com.
This news release contains forward-looking statements regarding tramiprosate (ALZHEMED(TM)), as well as regarding continuing and further development efforts. These statements are based on the current analysis and expectations of management. Drug development necessarily involves numerous risks and uncertainties, which could cause actual results to differ materially from this current analysis and these expectations. Analysis regarding the results of clinical trials may not provide definitive results regarding safety, tolerability or therapeutic benefits. There is no certainty that regulators will ultimately approve tramiprosate (ALZHEMED(TM)) for sale to the public. Risks and uncertainties may include: failure to demonstrate the safety, tolerability and efficacy of our product, that actual results may vary once the final and quality-controlled verification of data and analyses has been completed, the expense and uncertainty of obtaining regulatory approval, including from the FDA, and the possibility of having to conduct additional clinical trials. Further, even if regulatory approval is obtained, therapeutic products are generally subject to: stringent on-going governmental regulation, challenges in gaining market acceptance, and competition. Neither Neurochem Inc., nor Neurochem (International) Limited undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future events, or otherwise. Please see Neurochem Inc.'s Annual Information Form for further risk factors that might affect Neurochem Inc., Neurochem (International) Limited and their respective businesses.
For further information, please contact:
Lise Hebert, Ph.D.
Vice President, Corporate Communications
Tel: (450) 680-4572
lhebert@neurochem.com
SOURCE NEUROCHEM INC.
----------------------------------------------
Lise Hebert
Ph.D.
Vice President
Corporate Communications
(450) 680-4572
lhebert@neurochem.com
SHTP Shotpak to Be Featured on NBC Today Show
Shotpak Products Will Appear in an Elite Summer Beverage Segment
Jun 20, 2007 4:35:00 PM
Copyright Business Wire 2007
IRVINE, Calif.--(BUSINESS WIRE)--
Shotpak, Inc. (Pink Sheets:SHTP) will be featured in an exclusive segment on NBC Today titled: "Things You Need to Know about Summer Beverages."
Interested parties are advised to tune in to the segment (Date TBA) that will highlight the company's revolutionary concept of single shots of flavored liqueur and straight spirits in lightweight, durable and recyclable plastic stand-up pouches. When Daniel Barbossa, producer of NBC Today, was asked about Shotpak in the summer beverages segment, he stated: "Phil Lempert's 'Things You Need to Know about ... Summer Beverages' on NBC's Today gives viewers a look into some of the newest products that can make your summer more enjoyable."
Today, usually referred to as The Today Show to avoid ambiguity, is an American morning news and talk show airing weekday mornings on the NBC television network. It is the second-longest running American television series, behind Meet the Press, which also airs on NBC. Today has been the highest-rated morning news and talk show in the United States since the week of December 11, 1995.
Ignus Hattingh, CEO and Founder of Shotpak, Inc., stated, "The timing of this segment is perfect for our STR8UP line of premium distilled spirits launch. Being recognized, by NBC's Today Show, is an impressive tribute to our innovative product offerings that target consumers who enjoy an active lifestyle." Hattingh continued, "Our progressive development of the Ready to Drink (RTD) alcohol category allows us to meet and exceed our customer's requirements for a portable beverage. NBC's Today Show, is providing us with a national platform to enlighten the public to a product that adds value to any lifestyle. We are honored to be featured on America's top news magazine program."
Information on Shotpak, Inc.:
Shotpak, Inc., an Irvine, California based company, since 2003, is a leading distiller and innovator of cocktails and straight spirits in soft portable single serving stand up pouches. With over 50 years of combined experience and expertise in alcohol distilling, distribution and field marketing, retail placement and promotion as well as consumer trial and adoption, they prove to be a forerunner in the single serve Ready to Drink (RTD) alcohol category. With the successful launch of four premium vodka flavored drinks and four premium distilled spirits in January 2007, Shotpak has instantaneously captured national attention in the rapidly emerging $110 billion plus alcohol beverage industry. They are recognized for being visionaries with their award-winning spirits and revolutionary packaging which gives consumers a cost effective way to purchase spirits without the bulky bottle.
Shotpak products are packaged in single serving, lightweight, break-resistant, recyclable plastic pouches with a built-in spout making it easy to pour anywhere. Shotpak products are ideal for camping, boating, golfing, concerts, sporting events, or for anyone on-the-go. Made with recyclable plastic instead of glass, Shotpak products provide a safe alternative especially during summer activities. Shotpak, Inc. is immersed in a national roll-out through strategic distribution channels and is expected to be available in most major markets this year.
For more information about Shotpak, Inc. please visit us at: www.shotpakinc.com.
Source: Shotpak, Inc.
----------------------------------------------
Shotpak
Inc.
Serena Smith
Investor Relations
866-370-7074
SHTP Shotpak to Be Featured on NBC Today Show
Shotpak Products Will Appear in an Elite Summer Beverage Segment
Jun 20, 2007 4:35:00 PM
Copyright Business Wire 2007
IRVINE, Calif.--(BUSINESS WIRE)--
Shotpak, Inc. (Pink Sheets:SHTP) will be featured in an exclusive segment on NBC Today titled: "Things You Need to Know about Summer Beverages."
Interested parties are advised to tune in to the segment (Date TBA) that will highlight the company's revolutionary concept of single shots of flavored liqueur and straight spirits in lightweight, durable and recyclable plastic stand-up pouches. When Daniel Barbossa, producer of NBC Today, was asked about Shotpak in the summer beverages segment, he stated: "Phil Lempert's 'Things You Need to Know about ... Summer Beverages' on NBC's Today gives viewers a look into some of the newest products that can make your summer more enjoyable."
Today, usually referred to as The Today Show to avoid ambiguity, is an American morning news and talk show airing weekday mornings on the NBC television network. It is the second-longest running American television series, behind Meet the Press, which also airs on NBC. Today has been the highest-rated morning news and talk show in the United States since the week of December 11, 1995.
Ignus Hattingh, CEO and Founder of Shotpak, Inc., stated, "The timing of this segment is perfect for our STR8UP line of premium distilled spirits launch. Being recognized, by NBC's Today Show, is an impressive tribute to our innovative product offerings that target consumers who enjoy an active lifestyle." Hattingh continued, "Our progressive development of the Ready to Drink (RTD) alcohol category allows us to meet and exceed our customer's requirements for a portable beverage. NBC's Today Show, is providing us with a national platform to enlighten the public to a product that adds value to any lifestyle. We are honored to be featured on America's top news magazine program."
Information on Shotpak, Inc.:
Shotpak, Inc., an Irvine, California based company, since 2003, is a leading distiller and innovator of cocktails and straight spirits in soft portable single serving stand up pouches. With over 50 years of combined experience and expertise in alcohol distilling, distribution and field marketing, retail placement and promotion as well as consumer trial and adoption, they prove to be a forerunner in the single serve Ready to Drink (RTD) alcohol category. With the successful launch of four premium vodka flavored drinks and four premium distilled spirits in January 2007, Shotpak has instantaneously captured national attention in the rapidly emerging $110 billion plus alcohol beverage industry. They are recognized for being visionaries with their award-winning spirits and revolutionary packaging which gives consumers a cost effective way to purchase spirits without the bulky bottle.
Shotpak products are packaged in single serving, lightweight, break-resistant, recyclable plastic pouches with a built-in spout making it easy to pour anywhere. Shotpak products are ideal for camping, boating, golfing, concerts, sporting events, or for anyone on-the-go. Made with recyclable plastic instead of glass, Shotpak products provide a safe alternative especially during summer activities. Shotpak, Inc. is immersed in a national roll-out through strategic distribution channels and is expected to be available in most major markets this year.
For more information about Shotpak, Inc. please visit us at: www.shotpakinc.com.
Source: Shotpak, Inc.
----------------------------------------------
Shotpak
Inc.
Serena Smith
Investor Relations
866-370-7074
chris....my reply from TDA was regarding the acct holding 1 share SWNE
wahooooooooooooooooo!!! enjoy ":)
LOL :)
from ameritrade:
In regards to the reverse split from STATUS WINERY OF TUSCANY INC (SWNE), shareholders that are to receive the 500 round up shares of MCII will be updated when the shares are delivered from the company. This particular action will take several weeks due to the shares being delivered physically from the company. There is not an exact date for this to complete at this time.
If you need any further assistance please feel free to call or email at your convenience.
Thank you,
Cassie J.
Apex Reorganization and Safekeeping, TD AMERITRADE
Division of TD AMERITRADE, Inc.
LOL!!! :) runnnnnnnnnn!!! lol
NSHV .05/.052
NSHV .042/.048
all body parts crossed that it works out that way! LOL ;)
NSHV :) nice info! .04x2 .045x1
ohhhhh, i see...dang, that's nuts..lol
i tried...lol....no go
nope.....dangit! but i believe that confirms that i will get my 500 shares.
MCII ...prodigy acct now shows what i bought ...501 shares SWNEXZ
NSHV L2
MCII ut 5.00/11.00
NSHV .04x2 .042x1
AVVW .0006/.0007 2x2
NSHV .04/.05
thought it was 7.3M